Arbutus Biopharma Corp (ABUS) Stock Price & Analysis
Arbutus Biopharma Corp (ABUS) rose 0.24% to USD 4.25 as of June 10, 2026 at 06:42 UTC, according to Nexqual real-time market data.
ABUS last closed at USD 4.24; the session ranged USD 4.18–4.36 on volume of 1,072,407 shares. Market capitalization is $839.54M, with a 52-week range of USD 3.04–5.1 (NMS). Source: Nexqual, June 10, 2026 at 06:42 UTC.
Key Statistics (as of June 10, 2026 at 06:42 UTC)
| Price | USD 4.25 |
|---|---|
| Change | ▲ 0.24% (up) |
| Previous Close | USD 4.24 |
| Open | USD 4.29 |
| Day Range | USD 4.18 – 4.36 |
| 52-Week Range | USD 3.04 – 5.1 |
| Volume | 1,072,407 shares |
| Market Cap | $839.54M |
| Exchange | NMS |
Technical Analysis (ABUS)
Nexqual's technical model rates ABUS "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 06:42 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.41 (neutral) |
| vs SMA50 | Below (USD 4.38) |
| MACD | -0.01 (negative) |
Analyst Ratings (ABUS)
Wall Street analysts rate ABUS "None" based on 3 analysts, with a mean price target of USD 5.1 (range USD 4.9–5.42), per Nexqual as of June 10, 2026 at 06:42 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 5.1 |
| High Target | USD 5.42 |
| Low Target | USD 4.9 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (ABUS)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.06 |
| Revenue Estimate | $961,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.19 vs est -0.06 ▲ beat |
| 2025-12-31 | USD -0.01 vs est -0.06 ▲ beat |
| 2025-09-30 | USD -0.06 vs est -0.05 ▼ miss |
| 2025-06-30 | USD 0.01 vs est -0.09 ▲ beat |
Source: Nexqual, June 10, 2026 at 06:42 UTC.
Financials & Fundamentals (ABUS)
| Total Revenue | $191.44M |
|---|---|
| Revenue Growth (YoY) | +10054.50% |
| Gross Margin | +89.34% |
| Operating Margin | +94.41% |
| Profit Margin | +83.95% |
| ROE | +94.73% |
| Debt / Equity | 1.5 |
| Current Ratio | 54.26 |
| Total Cash | $95.23M |
| Total Debt | $3.91M |
| Free Cash Flow | $-90.41M |
Source: Nexqual, June 10, 2026 at 06:42 UTC.
Financial Health Score (ABUS)
Nexqual rates Arbutus Biopharma Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 06:42 UTC.
| Growth | Strong — Revenue +119% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $95M cash vs $4M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$90M, burning cash |
| Efficiency | Strong — ROE 95%, ROA 49.2% |
Ownership (ABUS)
| Insider Ownership | +20.46% |
|---|---|
| Institutional Ownership | +71.90% |
| Shares Outstanding | 197.54M |
| Float | 121.37M |
| Short % of Float | +12.79% |
Source: Nexqual, June 10, 2026 at 06:42 UTC.
Leadership (ABUS)
Arbutus Biopharma Corp is led by Lindsay Androski (age 48), President, CEO & Chairman, per Nexqual as of June 10, 2026 at 06:42 UTC.
| President, CEO & Chairman | Lindsay Androski (age 48) |
|---|---|
| Chief Financial Officer | Tuan Nguyen (age 49) |
Major Backers & Investors (ABUS)
Notable institutional backers of Arbutus Biopharma Corp include Morgan Stanley, Two Seas Capital Lp, Whitefort Capital Management, LP, according to Nexqual as of June 10, 2026 at 06:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 16.08% |
| Two Seas Capital Lp | 9.39% |
| Whitefort Capital Management, LP | 7.56% |
| Rubric Capital Management LP | 3.35% |
| Barclays Plc | 2.18% |
| Adar1 Capital Management, LLC | 1.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.53% |
| Vanguard Group | 6.71% |
| State Street | 4.46% |
| Geode Capital | 1.91% |
Source: Nexqual, June 10, 2026 at 06:42 UTC.
From Arbutus Biopharma Corp's Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
- Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
- The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.72 | ▲ 5.52% |
| ABEO | Abeona Therapeutics Inc. | USD 5.45 | ▼ 0.18% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 11.17 | ▲ 0.45% |
| ADMA | ADMA Biologics Inc | USD 8.12 | ▲ 1.88% |
| AFMDQ | Affimed N.V. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:42 UTC. This page is informational and not investment advice.